Sign in
WithdrawnPhase 2/3

Topical Everolimus in Patients With Tuberous Sclerosis Complex

Key facts

Who runs it
Hospices Civils de Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Status
Withdrawn
Phase
Phase 2/3
Started
Dec 2020
Ended
Dec 2024
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Everolimus
  • Placebo
Record updated
3 May 2021
Why it stopped
Pharmaceutical and financial difficulties

Who can take part

Age
0 years to 2 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients over the age of 2 years
  • With definite or possible diagnosis of TSC
  • With at least 3 FA, diagnosed by a dermatologist
  • Patients (or parents or legal guardians) who have provided written informed consent prior to participation in the study
  • Willing and able to comply with study requirements
  • With negative blood pregnancy test at the screening visit and using effective contraceptive methods for women of childbearing potential, up to 12 weeks after treatment discontinuation
  • Covered by national health insurance

Who cannot take part

  • Systemic treatment by sirolimus, everolimus, or any other immunosuppressive drug, during the previous 6 months
  • Use of topical tacrolimus or sirolimus on the face, during the previous 6 months
  • Destructive treatment (laser therapy, surgery, cryotherapy) of facial angiofibromas during the previous 6 months
  • Concomitant use of topical treatments that could affect facial erythema (e.g. Brimonidine)
  • Known internal organ involvement requiring systemic mTOR inhibitor in the next 6 months
  • Immunosuppression (immunosuppressive disease or immunosuppressive treatment)
  • Known chronic infectious disease Known hypersensitivity to mTOR inhibitor
  • Chronic renal insufficiency (estimated Glomerular Filtration Rate < 60 mls/min)
  • Uncontrolled diabetes
  • Chronic liver disease (SGOT or SGPT > 3 times upper normal limit)
  • Brest feeding or pregnant women, or women on childbearing age without any effective method of contraception during treatment and up to 12 weeks after treatment discontinuation
  • Neutropenia < 1000/mm3
  • Thrombopenia < 75,000/mm3
  • Uncontrolled dyslipidaemia
  • Subjects who, in the Investigator's opinion, are unable or unwilling to comply with the protocol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder characterized by the development of hamartomas in several organs (e.g. brain, heart, kidney, liver, lung), and skin in more than 90% of cases. Facial angiofibromas (FA), present in about 80% of patients, are a stigmatizing hallmark of the disease. Everolimus could be a candidate for use as a topical formulation to treat FA. This adaptive seamless Phase II/III study primary objective is to determine the dose of topical everolimus for treatment of FA and evaluate the efficacy and safety of topical everolimus versus placebo in patients with angiofibromas.

The 4 groups in the trial

  • Topical everolimus 0.1%Treatment being tested

    Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).

    Treatment: Everolimus

  • Topical everolimus 0.5%Treatment being tested

    Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).

    Treatment: Everolimus

  • Topical everolimus 1%Treatment being tested

    Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).

    Treatment: Everolimus

  • Topical placeboPlacebo, for comparison

    Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus.
Record updated
3 May 2021